Renal effects of targeted anticancer therapies

Nature Reviews Nephrology

Volumn 11, Issue 6, 2015, Pages 354-370

  Porta, Camillo ^a   Cosmai, Laura ^b   Gallieni, Maurizio ^c   Pedrazzoli, Paolo ^a   Malberti, Fabio ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b CREMONA HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; SORAFENIB; TRAMETINIB; VASCULOTROPIN RECEPTOR; VEMURAFENIB; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EVEROLIMUS; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A;

CHRONIC KIDNEY DISEASE; DIALYSIS; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; HUMAN; KIDNEY FUNCTION; NEPHROTOXICITY; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY PROXIMAL TUBULE; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROTO ONCOGENE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BEVACIZUMAB; CTLA-4 ANTIGEN; EVEROLIMUS; GENES, ERBB-1; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULES, PROXIMAL; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84930043826     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2015.15     Document Type: Review

References (167)

1. Launay-Vacher, V. et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the Renal Insufficiency and Anticancer Medications (IRMA) study. Cancer 110, 1376-1384 (2007).
2. Launay-Vacher, V. Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. Semin. Nephrol. 30, 548-556 (2010).
3. Christiansen, C. F., Johansen, M. B., Lengeberg, W. J., Fryzek, J. P. & Sørensen, H. T. Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study. Eur. J. Intern. Med. 22, 399-406 (2011).
4. Maw, T. T. & Fried, L. Chronic kidney disease in the elderly. Clin. Geriat. Med. 29, 611-624 (2013).
5. Murthy, V. H., Krumholz, H. M. & Gross, C. P. Participation in cancer clinical trials: race, sex, and age-based disparities. JAMA 291, 2720-2726 (2004).
6. Unger, J. M. et al. Comparison of survival outcomes among cancer patients treated in and out of clinical trial. J. Natl. Cancer Inst. 106, dju002 (2014).
7. US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4. 0 [online], http://evs. nci. nih. gov/ftp1/CTCAE/About. html (2009).
8. Porta, C. et al. Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. Cancer Med. 3, 1517-1526 (2014).
9. Ferrara, N., Hillan, K. J., Gerber, H. P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400 (2004).
10. Chu, Q. S. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin. Biol. Ther. 9, 263-271 (2009).
11. Chow, L. Q. & Eckhardt, S. G. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol. 25, 884-896 (2007).
12. Sonpavde, G. & Hutson, T. E. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr. Oncol. Rep. 9, 115-119 (2007).
13. Bukowski, R. M. Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma. Front. Oncol. 2, 13 (2012).
14. Izzedine, H., Rixe, O., Billemont, B., Baumelou, A. & Deray, G. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am. J. Kidney Dis. 50, 203-218 (2007).
15. Syrigos, K. N., Karapanagiotou, E., Boura, P., Manegold, C. & Harrington, K. Bevacizumab-induced hypertension: pathogenesis and management. Biodrugs 25, 159-169 (2011).
16. Sugimoto, H. et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J. Biol. Chem. 278, 12605-12608 (2003).
17. Stylianou, K. et al. Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration. Nephrol. Dial. Transplant. 26, 1742-1745 (2011).
18. George, B. A., Zhou, X. J. & Toto, R. Nephrotic syndrome after bevacizumab: case report and literature review. Am. J. Kidney Dis. 49, e23-e29 (2007).
19. Eremina, V. et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358, 1129-1136 (2008).
20. Zachary, I. Signaling mechanism mediating vascular protective actions of vascular endothelial growth factor. Am. J. Physiol. 280, C1375-C1386 (2001).
21. Mourad, J. J., des Guetz, G., Debbabi, H. & Levy, B. I. Blood pressure rise following angiogenesis inhibition by bevacizumab: a crucial role for microcirculation. Ann. Oncol. 19, 927-934 (2008).
22. Yao, S. K. et al. Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation 86, 1302-1309 (1992).
23. Hicklin, D. J. & Ellis L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23, 1011-1027 (2005).
24. Mancia, G. et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J. Hypertens. 25, 1751-1762 (2007).
25. Izzedine, H. et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann. Oncol. 20, 807-815 (2009).
26. BC Cancer Agency Cancer Management Guidelines. Management guidelines of bevacizumab-related side effects in patients with colorectal cancer [online], http://www. bccancer. bc. ca/NR/rdonlyres/6D39414F-EC1A-4BE2-9ACB-6DE017C9B4C4/19258/Managementforbevacizumabsideeffects-1Dec06. pdf (2006).
27. Porta, C., Paglino, C., Imarisio, I. & Bonomi, L. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents: the case of sorafenib and sunitinib. Clin. Exp. Med. 7, 127-134 (2007).
28. MacFarlane, R. et al. The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy. Cancer 118, 365-370 (2012).
29. Khosravan, R. et al. Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J. Clin. Pharmacol. 50, 472-481 (2009).
30. Gupta, S. et al. Safety and efficacy of targeted agents in metastatic kidney cancer patients with renal dysfunction. Anticancer Drugs 22, 794-800 (2011).
31. Méndez-Vidal, M. J., Martínez Ortega, E., Montesa Pino, A., Pérez Valderrama, B. & Viciana, R. Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma. Cancer Metastasis Rev. 31 (Suppl. 1), S19-S27 (2012).
32. Garnier-Viougeat, N. et al. Pharmacokinetics of bevacizumab in haemodialysis. Nephrol. Dial. Transplant. 22, 975 (2007).
33. Izzedine, H., Etienne-Grimaldi, M. C., Renée, N., Vignot, S. & Milano, G. Pharmacokinetics of sunitinib in hemodialysis. Ann. Oncol. 20, 190-192 (2009).
34. Masini, C. et al. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int. 110, 692-698 (2012).
35. Shetty, A. V. et al. Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience. Clin. Genitourin. Cancer 12, 348-353 (2014).
36. Porta, C., Paglino, C., Imarisio, I. & Ferraris, E. Sorafenib tosylate in advanced kidney cancer: past, present and future. Anticancer Drugs 20, 409-415 (2009).
37. Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004).
38. Crona, D. J., Keisler, M. D. & Walko, C. M. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors. Ann. Pharmacother. 47, 1685-1696 (2013).
39. Ryan, A. J. & Wedge, S. R. ZD6474-a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br. J. Cancer 92 (Suppl. 1), S6-S13 (2005).
40. Bellini, E. et al. Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism. Ann. Oncol. 22, 988-990 (2011).
41. Mir, O., Coriat, R., Boudou-Rouquette, P., Durand, J. P. & Goldwasser, F. Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications. Ann. Oncol. 23, 280-281 (2012).
42. Shen, H., Yang, Z., Zhao, W., Zhang, Y. & Rodrigues, A. D. Assessment of vandetanib as an inhibitor of various human renal transporters: inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance. Drug Metab. Dispos. 41, 2095-2103 (2013).
43. Morrissey, K. M., Stocker, S. L., Wittwer, M. B., Xu, L. & Giacomini, K. M. Renal transporters in drug development. Annu. Rev. Pharmacol. Toxicol. 53, 503-529 (2013).
44. Miller, A. A. et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J. Clin. Oncol. 27, 1800-1805 (2009).
45. Parsa, V., Heilbrun, L., Smith, D., Sethi, A. & Vaishampayan, U. Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function. Clin. Genitourin. Cancer 7, E10-E15 (2009).
46. Khan, G. et al. Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Ann. Oncol. 21, 1618-1622 (2010).
47. Ferraris, E. et al. Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysis. Tumori 95, 542-544 (2009).
48. Kennoki, T. et al. Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center. Jpn. J. Clin. Oncol. 41, 647-655 (2011).
49. Weil, A. et al. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment. Clin. Pharmacokinet. 49, 607-618 (2010).
50. Buchdunger, E., O'Reilly, T. & Wood, J. Pharmacology of imatinib (STI571). Eur. J. Cancer 38 (Suppl. 5), S28-S36 (2002).
51. Wang-Rosenke, Y. et al. Tyrosine kinase inhibition by imatinib slows progression in chronic ant-thy1 glomerulosclerosis of the rat. BMC Nephrol. 14, 223 (2013).
52. Elmholdt, T. R., Buus, N. H., Ramsing, M. & Olesen, A. B. Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial. J. Eur. Acad. Dermatol. Venereol. 27, 779-784 (2013).
53. Wallace, E. & Gewin, L. Imatinib: novel treatment of immune-mediated kidney injury. J. Am. Soc. Nephrol. 24, 694-701 (2013).
54. Wallace, E., Fogo, A. B. & Schulman, G. Imatinib therapy for non-infection-related type II cryoglobulinemia with membranoproliferative glomerulonephritis. Am. J. Kidney Dis. 59, 122-125 (2012).
55. Chandran, S. et al. Imatinib in the treatment of nephrogenic systemic fibrosis. Am. J. Kidney Dis. 53, 129-132 (2009).
56. Savikko, J., Rintala, J. M., Rintala, S. E., Koskinen, P. K. & von Willebrand. E. Early short-term imatinib treatment is sufficient to prevent the development of chronic allograft nephropathy. Nephrol. Dial. Transplant. 26, 3026-3032 (2011).
57. Iyoda, M. et al. Long and short-term treatment with imatinib attenuates the development of chronic kidney disease in experimental anti-glomerular basement membrane nephritis. Nephrol. Dial. Transplant. 28, 576-584 (2013).
58. Peng, B., Lloyd, P. & Schran, H. Clinical pharmacokinetics of imatinib. Clin. Pharmacokinet. 44, 879-894 (2005).
59. Gibbons, J. et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J. Clin. Oncol. 26, 570-576 (2008).
60. Judson, I. R. Imatinib for patients with liver or kidney dysfunction: no need to modify the dose. J. Clin. Oncol. 26, 521-522 (2008).
61. Tong, W. G. et al. Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. Cancer 116, 3152-3159 (2010).
62. Demetri, G. D. et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J. Clin. Oncol. 31, 2485-2492 (2013).
63. Porta, C., Paglino, C. & Mosca, A. Targeting PI3K/Akt/mTOR signaling in cancer. Front. Oncol. 4, 64 (2014).
64. Vogelbacher, R., Wittmann, S., Braun, A., Daniel, C. & Hugo, C. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 84, 1492-1499 (2007).
65. Baas, M. C. et al. Cyclosporine versus everolimus: effects on the glomerulus. Clin. Transplant. 27, 535-540 (2013).
66. Keller, K. et al. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy. Nephrol. Dial. Transplant. 21, 2724-2735 (2006).
67. Nakagawa, S., Nishihara, K., Inui, K. & Masuda, S. Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury. Eur. J. Pharmacol. 696, 143-154 (2012).
68. Hiatt, W. R., Nissen, S. E. & Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration. New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation: report from the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration, November 16, 2005, Rockville, Md. Circulation 113, e394-e395 (2006).
69. Bertoni, E. et al. Posttransplant proteinuria associated with everolimus. Transplant Proc. 41, 1216-1217 (2009).
70. Schmidinger, M. & Bellmunt, J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat. Rev. 36, 416-424 (2010).
71. Oroszlán, M. et al. Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway. Transpl. Immunol. 23, 125-132 (2010).
72. Rodriguez-Pascual, J., Cheng, E., Maroto, P. & Duran, I. Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Anticancer Drugs 21, 478-486 (2010).
73. Barthélémy, P. et al. mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice. Crit. Rev. Oncol. Hematol. 88, 42-56 (2013).
74. Porta, C. et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur. J. Cancer 47, 1287-1298 (2011).
75. Aapro, M. et al. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Ann. Oncol. 25, 763-773 (2014).
76. Thiery-Vuillemin, A. et al. Hemodialysis does not affect everolimus pharmacokinetics: two cases of patients with metastatic renal cell cancer. Ann. Oncol. 23, 2992-2993 (2012).
77. van Rooijen, J. M. & de Vries, E. G. Hemodialysis: no reason to withhold everolimus. Cancer Chemother. Pharmacol. 71, 273-274 (2013).
78. Lunardi, G. et al. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series. Clin. Ther. 31, 1812-1819 (2009).
79. Rosell, R. et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958-967 (2009).
80. Ciardiello, F. & Tortora, G. Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin. Investig. Drugs 11, 755-768 (2002).
81. Voets, T. et al. TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. J. Biol. Chem. 279, 19-25 (2004).
82. Groenestege, W. M. et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J. Clin. Invest. 117, 2260-2267 (2007).
83. Fakih, M. G., Wilding, G. & Lombardo, J. Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin. Colorectal Cancer 6, 152-156 (2006).
84. Tejpar, S. et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol. 8, 387-394 (2007).
85. Schrag, D., Chung, K. Y., Flombaum, C. & Saltz, L. Cetuximab therapy and symptomatic hypomagnesemia. J. Natl. Cancer Inst. 97, 1221-1224 (2005).
86. Izzedine, H. et al. Electrolyte disorders related to EGFR-targeting drugs. Crit. Rev. Oncol. Hematol. 73, 213-219 (2010).
87. Fakih, M. G. Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia. Oncology 22, 74-76 (2008).
88. Maliakal, P. & Ledford. A. Electrolyte and protein imbalance following anti-EGFR therapy in cancer patients: a comparative study. Exp. Ther. Med. 1, 307-311 (2010).
89. Dimke, H. et al. Effects of the EGFR inhibitor erlotinib on magnesium handling. J. Am. Soc. Nephrol. 21, 1309-1316 (2010).
90. Costa, A., Tejpar, S., Prenen, H. & Van Cutsem, E. Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents. Target. Oncol. 6, 227-233 (2011).
91. Krens, L. L. et al. Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction. Cancer Chemother. Pharmacol. 73, 1303-1306 (2014).
92. Aldoss, I. T., Plumb, T., Zhen, W. K., Lydiatt, D. D. & Ganti, A. K. Cetuximab in hemodialysis: a case report. Head Neck 31, 1647-1650 (2009).
93. Fontana, E., Pucci, F. & Ardizzoni, A. Colorectal cancer patient on maintenance dialysis successfully treated with cetuximab. Anticancer Drugs 25, 120-122 (2014).
94. Koch, T. et al. Antibody-dependent cellular cytotoxicity in patients on chronic hemodialysis. Am. J. Nephrol. 38, 379-387 (2013).
95. Rossi, A. et al. Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases. Lung Cancer 47, 421-423 (2005).
96. Del Conte, A. et al. Complete metabolic remission with gefitinib in a hemodialysis patient with bone metastases from non-small cell lung cancer. Anticancer Res. 34, 319-322 (2014).
97. Togashi, Y. et al. Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis. J. Thorac. Oncol. 5, 601-605 (2010).
98. Bersanelli, M., Tiseo, M., Artioli, F., Lucchi, L. & Ardizzoni, A. Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis. Anticancer Res. 34, 3185-3188 (2014).
99. Thomas, N. E. BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res. 16, 97-103 (2006).
100. Wan, P. T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004).
101. Regnier-Rosencher, E. et al. Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas. Br. J. Dermatol. 169, 934-948 (2013).
102. Launay-Vacher, V. et al. Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients. Cancer 120, 2158-2163 (2014).
103. Ascierto, P. A. et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J. Clin. Oncol. 31, 3205-3211 (2013).
104. Hauschild, A. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365 (2012).
105. Green, J. S., Norris, D. A. & Wisell, J. Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases. Br. J. Dermatol. 169, 172-176 (2013).
106. Iddawela, M. et al. Safety and efficacy of vemurafenib in end stage renal failure. BMC Cancer 13, 581 (2013).
107. Flaherty, K. T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF v600 mutations. N. Engl. J. Med. 367, 1694-1703 (2012).
108. Goldenberg, M. M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther. 21, 309-318 (1999).
109. Harbeck, N. et al. HER2 dimerization inhibitor pertuzumab-mode of action and clinical data in breast cancer. Breast Care (Basel) 8, 49-55 (2013).
110. Burris, H. A. 3rd. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 9 (Suppl. 3), 10-15 (2004).
111. Boyraz, B. et al. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Curr. Med. Res. Opin. 29, 405-414 (2013).
112. Russo, G. et al. Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer. Intern. Emerg. Med. 7, 439-446 (2012).
113. Kaufman, B. et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J. Clin. Oncol. 27, 5529-5537 (2009).
114. Slamon, D. et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365, 1273-1283 (2011).
115. Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687-697 (2010).
116. Micallef, R. A., Barrett-Lee, P. J., Donovan, K., Ashraf, M. & Williams, L. Trastuzumab in patients on haemodialysis for renal failure. Clin. Oncol. (R. Coll. Radiol. ) 19, 559 (2007).
117. Piacentini, F., Omarini, C. & Barbieri, E. Lapatinib and renal impairment: a case report. Tumori 99, e134-e135 (2013).
118. Costa Reis, A. P., Russo, P., Gallucci, S. & Sullivan, K. E. Control of cell proliferation in lupus nephritis: the role of miRNAs and HER2 [abstract]. Arthritis Rheumatol. 66 (Suppl. S3), S194 (2014).
119. Walunas, T. L. et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1, 405-413 (1994).
120. Spanou, Z. et al. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J. Am. Soc. Nephrol. 17, 2919-2927 (2006).
121. Voskens, C. J. et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE 8, e53745 (2013).
122. Izzedine, H. et al. Kidney injuries related to ipilimumab. Invest. New Drugs 32, 769-773 (2014).
123. Fadel, F., El Karoui, K. & Knebelmann, B. Anti-CTLA4 antibody-induced lupus nephritis. N. Engl. J. Med. 361, 211-212 (2009).
124. Weber, J. S. et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J. Clin. Oncol. 26, 5950-5956 (2008).
125. O'Day, S. J. et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann. Oncol. 21, 1712-1717 (2010).
126. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011).
127. Rodig, S. J. & Shapiro, G. I. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr. Opin. Investig. Drugs 11, 1477-1490 (2010).
128. Camidge, D. R. et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 13, 1011-1019 (2012).
129. Shaw, A. T. et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385-2394 (2013).
130. Seimetz, D., Lindhofer, H. & Bokemeyer, C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev. 36, 458-467 (2010).
131. Brosnan, E. M. et al. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer 120, 664-674 (2014).
132. Martín Martorell, P., Huerta Alvaro, M., Solís Salguero, M. A. & Insa Molla, A. Crizotinib and renal insufficiency: a case report and review of the literature. Lung Cancer 84, 310-313 (2014).
133. Gastaud, L. et al. Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma. Lung Cancer 82, 362-364 (2013).
134. Lin, Y. T. et al. Development of renal cysts after crizotinib in advanced ALK-positive non-small-cell lung cancer. J. Thorac. Oncol. 9, 1720-1725 (2014).
135. Heigener, D. F. & Reck, M. Crizotinib. Recent Results Cancer Res. 201, 197-205 (2014).
136. Houk, B. E. et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother. Pharmacol. 66, 357-371 (2010).
137. Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604-612 (2009).
138. Janus, N. et al. Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study. Ann. Oncol. 24, 501-507 (2013).
139. Porta, C. & Szczylik, C. Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treat. Rev. 35, 297-307 (2009).
140. Finkel, K. W. & Howard, S. C. Onco-nephrology: an invitation to new field. J. Clin. Oncol. 32, 2389-2390 (2014).
141. Perazella, M. A., Berns, J. S. & Rosner, M. H. Cancer and the kidney: the growth of onco-nephrology. Adv. Chronic Kidney Dis. 21, 4-6 (2014).
142. Zhu, X., Wu, S., Dahut, W. L. & Parikh, C. R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am. J. Kidney Dis. 49, 186-193 (2007).
143. Wu, S., Kim, C., Baer, L. & Zhu, X. Bevacizumab increases risk for severe proteinuria in cancer patients. J. Am. Soc. Nephrol. 21, 1381-1389 (2010).
144. Ranpura, V., Pulipati, B., Chu, D., Zhu, X. & Wu, S. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am. J. Hypert. 23, 160-168 (2010).
145. Van Cutsem, E. et al. Addition of aflibercept to fluorouracil, leucovorin and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30, 3499-3506 (2012).
146. Qi, W. X., Shen, Z., Tang, L. N. & Yao, Y. Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis. Clin. Drug Investig. 34, 231-240 (2014).
147. Zhu, X., Stergiopoulos, K. & Wu, S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 48, 9-17 (2009).
148. Qi, W. X. et al. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. Cancer Chemother. Pharmacol. 71, 431-439 (2013).
149. Zhang, Z. F., Wang, T. Liu, L. H. & Guo, H. Q. Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. PLoS ONE 9, e90135 (2014).
150. Qi, W. X., He, A. N., Shen, Z. & Yao, Y. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. Br. J. Clin. Pharmacol. 76, 348-357 (2013).
151. Li, Y. et al. Incidence and risk of Sorafenib-induced hypertension: a systematic review and meta-analysis J. Clin. Hypertens. (Greenwich) 16, 177-185 (2014).
152. Funakoshi, T., Latif, A. & Galsky, M. D. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis. J. Hum. Hypertens. 27, 601-611 (2013).
153. Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
154. Llovet, J. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
155. Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 303-312 (2013).
156. Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449-456 (2008).
157. Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514-523 (2011).
158. Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520-529 (2012).
159. Hudes, G. et al. Temsirolimus, interferon, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2781 (2007).
160. Chen, P., Wang, L., Li, H., Liu, B. & Zou, Z. Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: a meta-analysis. Oncol. Lett. 5, 1915-1920 (2013).
161. Cao, Y., Liao, C., Tan, A., Liu, L. & Gao, F. Meta-analysis of incidence and risk of hypomagnesemia with cetuximab for advanced cancer. Chemotherapy 56, 459-465 (2010).
162. Petrelli, F., Borgonovo, K., Cabiddu, M., Ghilardi, M. & Barni, S. Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin. Drug Saf. 11 (Suppl. 1), S9-19 (2012).
163. Cao, Y., Liu, L., Liao, C., Tan, A. & Gao, F. Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer. Cancer Chemother. Pharmacol. 66, 37-42 (2010).
164. Kim, E. S. et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372, 1809-1818 (2008).
165. Wan, H. L. & Yao, N. S. Acute renal failure associated with gefitinib therapy. Lung 184, 249-250 (2006).
166. Kumasaka, R. et al. Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy. Clin. Oncol. 22, 2504-2505 (2004).
167. Miller, V. A. et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 13, 528-538 (2012).